Pieris Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview

Palvella Therapeutics

29/10/2021 12:16

* Pieris Pharmaceuticals Inc  PIRS.OQ   PIRS.O  is expected
to show a rise in quarterly revenue when it reports results on
November 2 (estimated). 
* The Boston, Massachusetts-based company is expected to report 
a 80.9% increase in revenue to $5.317 million from $2.94 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Pieris Pharmaceuticals
Inc is for a loss of 24 cents per share. For the same quarter
last year, the company reported a loss of 26 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $8.5​, about 44.8% above​ its last
closing price of $4.69. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.25       -0.26      -0.25     Beat    5.7
 Mar. 31 2021  -0.17       -0.17      -0.07     Beat    58.8
 Dec. 31 2020              -0.24      -0.26     Missed  -9.9​
 Sep. 30 2020  -0.14       -0.13      -0.26     Missed  -99.7
 Jun.          -0.18​      -0.17      -0.09     Beat    47.6​
 30​ 2020​                                              
 Mar. 31 2020  -0.19       -0.17      -0.07     Beat    57.8​
 Dec. 31 2019  -0.23       -0.28      -0.06     Beat    78.4
 Sep. 30 2019  -0.23       -0.23      -0.05     Beat    78.2
 This summary was machine generated October 29 at 11:16 GMT.  All
figures in US dollars unless otherwise stated